Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoLLY -0.18%96 EV-to-EBITDA is 29.74 as of Jul. 29, 2026, which is 13% above its 10-year median of 26.36. GuruFocus rates LLY with a GF Score™ of 96/100 and a GF Value™ of $1,439.21 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 744 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 80.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eli Lilly and Co's enterprise value is $1,124,590 Mil.
Eli Lilly and Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $37,817 Mil. Therefore, Eli Lilly and Co's EV-to-EBITDA for today is 29.74.
The historical rank and industry rank for Eli Lilly and Co's EV-to-EBITDA or its related term are showing as below:
LLY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.08 Med: 26.36 Max: 69.97
Current: 29.74
During the past 13 years, the highest EV-to-EBITDA of Eli Lilly and Co was 69.97. The lowest was 16.08. And the median was 26.36.
LLY's EV-to-EBITDA is ranked worse than 80.24% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs LLY: 29.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Eli Lilly and Co (NYSE:LLY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eli Lilly and Co's PE Ratio (TTM) for today is calculated as:
Eli Lilly and Co's share price for today is $1218.405.
Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Eli Lilly and Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's EV-to-EBITDA falls into.
Eli Lilly and Co's current Enterprise Value is $1,124,590 Mil.
Eli Lilly and Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $37,817 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (LLY) has a EV-to-EBITDA of 29.74 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eli Lilly and Co. This is 13% above median its historical median of 26.36. Over the past decade, Eli Lilly and Co's EV-to-EBITDA has ranged from 16.08 to 69.97. According to the industry distribution chart, Eli Lilly and Co ranks #597 out of 744 companies in the Drug Manufacturers industry, placing it in the top 80.2%.
Is Eli Lilly and Co's EV-to-EBITDA too high?
Eli Lilly and Co's current EV-to-EBITDA of 29.74 is 13% above median its 10-year median of 26.36. Over the past 10 years, this metric has ranged from a low of 16.08 to a high of 69.97. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Eli Lilly and Co's value of 29.74 is 129.1% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #597 out of 744 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EV-to-EBITDA compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #597 out of 744 companies for EV-to-EBITDA. This places Eli Lilly and Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Eli Lilly and Co's value of 29.74 is 129.1% above this benchmark. Historically, Eli Lilly and Co's own EV-to-EBITDA has ranged from 16.08 to 69.97 over the past decade. While the company's 10-year median is 26.36 vs. the industry median of 12.98, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current EV-to-EBITDA of 29.74 is 129.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eli Lilly and Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current EV-to-EBITDA is 29.74, which is 13% above median its own 10-year median of 26.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is $1,439.21, compared to a current price of $1,218.41 — trading 15.3% below its estimated fair value. The current EV-to-EBITDA is 29.74, which is 13% above median its 10-year median of 26.36 and 129.1% above the Drug Manufacturers industry median of 12.98. Eli Lilly and Co's overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eli Lilly and Co (LLY), the current EV-to-EBITDA is 29.74 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of $1,218.41 is trading 15.3% below its estimated GF Value™ of $1,439.21.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for LLY:
EV-to-EBITDA: 29.74 (13% above median its 10-year median of 26.36)
GF Value™: $1,439.21 vs. price of $1,218.41 (15.3% below fair value)
Industry Position: 129.1% above the Drug Manufacturers median (#597 of 744)
No single metric tells the full story. See the LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score
Get the complete analysis for LLY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LLY has been successfully added to your 
